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ABSTRACT 
 
EFFECTS OF HISTONE DEACETYLASE INHIBITORS ON VITAMIN D ACTIVITY IN 
HUMAN BREAST CANCER CELLS 
 
SEPTEMBER 2013 
 
BROOKE S. SAVAGE, B.A., HOFSTRA UNIVERSITY 
 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Richard J. Wood 
 
Breast cancer is one of the leading causes of death among cancer cases in 
women worldwide. Ultimately, cancer is the result of a combination of 
environmental and genetic factors that contribute to alterations in cellular control 
of proliferation, differentiation and programmed cell death. Vitamin D had been 
emerging as a potentially important nutrient in the prevention and treatment of 
cancer due to its ability to modulate proliferation, apoptosis, invasion and 
metastasis in vivo in animal cancer models and in vitro cell culture studies. To 
accomplish these cellular effects, Vitamin D exerts its biological activity via the 
binding of its hormonal metabolite 1,25(OH) 2D3 to a specific, high-affinity, 
intracellular vitamin D receptor (VDR). Although VDR expression can be identified 
in mammary cancer cell lines, levels are often reduced compared to non-cancerous 
cells, which could limit vitamin D-induced gene expression and function in these 
cells.  In addition, changes in chromatin structure, associated with epigenetic 
modifications of nuclear histone proteins, can lead to changes in gene expression, 
including the suppression of important “tumor suppressor” genes, thereby 
promoting carcinogenesis.  Our study investigated the extent to which two 
compounds with histone deacetylase inhibitor (HDACI) activity, trichostatin A 
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(TSA), a well-known and potent HDACI, and sulforaphane (SFN), a bioactive food 
component with HDACI activity, can influence the expression of some important 
genes involved in vitamin D action and metabolism in cells. The genes investigated 
were: CYP24A1, which codes for a 24-hydroxylase that deactivates 1,25(OH) 2D3; 
CYP27B1, which codes for a 1α-hydroxylase that activates 25(OH)D to the 1,25(OH) 
2D3 hormone; VDR, the nuclear receptor transcription factor that is activated by 
1,25(OH) 2D3; and TRPV6, which codes for a calcium-specific channel implicated in 
breast cancer cell invasiveness.  
We found that in MCF-7 breast cancer cells, 1,25(OH)2D3 treatment alone 
induced the expression of VDR mRNA (in 1 of 2 studies), CYP24A1 mRNA (in both 
studies) and CYP27B1(in 1 of 1 study where measured). Surprisingly, TRPV6 mRNA 
expression was not evident in MCF-7 cells in either the presence or absence of 
1,25(OH)2D3. The HDACI TSA alone increased expression of VDR mRNA, but SFN 
alone had no effect. Importantly, VDR mRNA was increased by co-treatment of 
1,25(OH)2D3 and TSA compared to 1,25(OH)2D3  alone in Experiment 1 with a 
similar, but not statistically significant, trend in Experiment 2. As expected, 
1,25(OH)2D3 markedly increased CYP24A1 mRNA. Unexpectedly, treatment with 
either TSA or SFN alone increased CYP24A1 mRNA, suggesting that endogenous 
expression of CYP24A1 may be normally suppressed in MCF-7 cells by epigenetic 
mechanisms involving histone acetylation status. An apparent increase in CYP24A1 
mRNA following co-treatment of TSA with 1,25(OH)2D3 in both experiments was not 
statistically significant. SFN co-treatment with 1,25(OH)2D3 also did not cause a 
further increase in CYP24A1 mRNA. 1,25(OH)2D3 treatment increased CYP27B1 
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expression, but co-treatment with TSA had no additional effect. In contrast, co-
treatment of SFN and 1,25(OH)2D3 inhibited much of the positive effects of vitamin 
D. TSA is already being used as a co-treatment in cancer therapy. Vorinostat, a drug 
with the same chemical structure as TSA, is being investigated in hundreds of 
clinical trials. (Marks & Breslow, 2007) Our findings support further study of the 
effects of the HDACI TSA in breast cancer, and suggest that this HDACI may be 
beneficial in augmenting vitamin D cellular responsiveness.  
ix 
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CHAPTER 1 
LITERATURE REVIEW 
1.1 Breast Cancer 
Cancer represents a group of diseases that all share the same fundamental 
feature, the abnormal growth of cells. The National Cancer Institute (NCI) defines 
cancer as a collection of diseases that results from the breakdown of regulatory 
mechanisms, due to damaged DNA, which govern normal cell behavior. When cell 
regulation is lost, cancer cells uncontrollably grow and divide, ultimately spreading 
throughout the body and thus interfering with the normal function of tissues and 
organs. (National Cancer Institute, 2013) 
According to the American Cancer Society, breast cancer is the second most 
common cancer, to lung cancer, among women in the United States; it represents 
26% of all cancer cases in women. Breast cancer forms in the breast tissue, usually 
the ducts and lobules, and can occur in both men and women, but male cases are 
rare. Although incidence rates have been decreasing over the last decade, 12% of 
women in the United States will develop invasive breast cancer at one point in their 
lifetime; and it is more likely to occur in white women than African American, 
Hispanic or Indian women. Estimates for 2013 show just over 232,000 new cases of 
breast cancer will be diagnosed among women in the US; and about 40,000 women 
will die of breast cancer. (American Cancer Society, 2013) 
Breast cancer has emotional and physical implications on the women it 
affects. Treatment can be long and arduous, leading to depression, decreased 
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physical ability, family strain and even financial hardship. The financial burden is 
also felt by the society as a whole; according to the NCI, in 2006 breast cancer 
totaled $14 billion in total health expenditures, and additionally $16 billion in 
indirect mortality cost, such as loss of productivity from premature death. Clearly 
breast cancer is a far-reaching public health issue with serious implications and 
consequences. (National Cancer Institute, 2013) 
Breast cancer is caused by an interaction between genetic and environmental 
factors. Risk factors include gender, age, race and genetics; there are other risk 
factors that have the potential to be modified, thus offering the opportunity to 
develop useful preventative strategies.  In vivo and in vitro studies strongly suggest 
a relationship between certain nutrient exposure and breast cancer risk. (Vera-
Ramirez et al., 2013) A review of observational studies identified that alcohol intake 
as well as a high-energy intake were associated with an increased risk of breast 
cancer, whereas low-fat and high-fiber diets reduced the risk. (Thomson, 2012)  
Preclinical studies support a potential role for vitamin D in breast cancer prevention 
and treatment, and low vitamin D intake in women has been implicated as a risk 
factor for breast cancer (Lee, 2011), but the need for vitamin D supplementation in 
breast cancer prevention remains controversial.   
1.2 Vitamin D and Breast Cancer 
Although the relationship between vitamin D and breast cancer remains 
unclear, there is increasing evidence that optimal vitamin D status does play a 
marginal role in reducing breast cancer risk. (Bertone-Johnson, 2009) There have 
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been numerous experimental studies to show that vitamin D inhibits cellular 
proliferation as well as induces differentiation and apoptosis in both normal and 
transformed breast cells. (Colston, 2008; Vera-Ramirez et al., 2013; Welsh, 2011)   
Case-control studies have shown a significant and inverse association 
between vitamin D levels and breast cancer risk. (Abbas et al., 2008; Blackmore et 
al., 2008; Knight, Lesosky, Barnett, Raboud, & Vieth, 2007; Rossi et al., 2009)  
Ecological and observational studies yield the strongest evidence that higher serum 
25-hydroxyvitamin D levels are associated with a reduce risk of breast cancer. A 
meta-analysis of six observational studies concluded that there is a 50% reduction 
in incidence rate for breast cancer associated with an increased serum 25 
hydroxyvitamin D from 24nmole/L to 78nmol/L. (Grant, 2010) Another meta-
analysis looking at vitamin D intake and breast cancer risk reflected a trend towards 
lower risk of breast cancer with intakes of vitamin D ≥ 400 IU/day. (Hong, Tian, & 
Zhang, 2012)  
Despite this evidence, vitamin D supplementation trials have not shown 
convincing effects of vitamin D supplementation on primary prevention of breast 
cancer. The Women’s Lifestyle and Health Cohort Study looked at 42,000 Swedish 
women and examined solar exposure and vitamin D intake to find serum levels had 
no significant relationship to breast cancer risk. (Kuper et al., 2009) This study 
concludes a need for large randomized control trials, designed to adjust for 
confounding variables, in order to delineate the possible relationship between 
serum vitamin D status and breast cancer risk. The Women’s Health Initiative study 
supplemented over 36,000 women with 1,000 mg of calcium and 400IU of vitamin 
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D3 daily for 7 years, and they did not find a strong reduction of breast cancer risk 
among the supplemented group. (Prentice et al., 2013) Despite those outcomes, in 
vivo and in vitro research is still showing vitamin D3 to have chemo-protective 
effects, warranting further investigation.  
1.3 Vitamin D Sources 
Optimal vitamin D status is dependent upon a variety of factors. Vitamin D is 
obtained from both dietary sources and from cutaneous synthesis with exposure to 
UVB sunlight. The Recommended Dietary Allowances (RDA) for healthy adults ages 
19 to 50 is 15μg (600IU) daily; this equates to a serum level of 50nM. (National 
Institute of Health, 2011) Natural dietary sources include oily fish, such as mackerel 
and salmon, but the major dietary sources are fortified dairy products and cereal 
grains. (Stipanuk & Holick, 2006) A cup of skim, 1%, 2% or whole milk fortified with 
vitamin D contains 115 to 125 IU, which amounts to about 20% of the RDA (600 
IU/day). A cup of fortified breakfast cereal contains about 40 IU, about 7% of the 
RDA. Since it can be difficult to obtain the recommended 600 IU of vitamin D from 
dietary sources, vitamin D supplements are readily available. 
Daily sunlight exposure is the main contributing factor, 90%, to vitamin D 
status, and can be sufficient to meet vitamin D requirements in certain situations. 
However, the time of day, season of the year, and the geographical latitude have 
dramatic effects on the amount of solar UVB radiation that reaches the earth’s 
surface. In winter months, the ability to produce vitamin D in the skin is reduced 
because the vitamin D-producing UVB photons pass through the ozone layer at an 
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oblique angle and are absorbed to a greater extent by the ozone reducing surface 
radiation. In contrast, the relative position of the sun in spring and summer months 
allows for less ozone UVB absorption and therefore more UVB photons to penetrate 
to the earth’s surface. At a latitude of 42°N (Boston), sunlight is incapable of 
producing vitamin D in the skin from November through February. (Stipanuk & 
Holick, 2006)  Since our exposure to sunlight provides 90% of our vitamin D 
exposure, people living in more northern and southern latitudes will frequently 
show insufficient vitamin D levels during their respective winter months.  
The influence of latitude on cutaneous vitamin D production has initiated a 
hypothesis as to why women in the northern hemisphere, North America and 
northern European countries, exhibit the highest incidence rate of breast cancer, 
where women in regions with relatively more sun exposure are relatively protected 
from breast cancer. (Suba, 2012) If this hypothesis is correct, achieving a higher 
vitamin D status in these women living in areas that put them at a higher risk of 
developing breast cancer could help to prevent the initiation and development of 
the disease.  
1.3.1 Vitamin D Absorption, Transport, Metabolism and Biodegradation 
The first step of vitamin D activation and metabolism involves the formation 
of vitamin D3 in the skin from ultraviolet irradiation at 290nm – 315nm (P. H. 
Anderson, May, & Morris, 2003) , or vitamin D3 (cholecalciferol) intake from eating 
certain animal-based foods in the diet or vitamin D2 (ergocalciferol) derived from 
plant sources. Vitamin D is fat soluble and is incorporated with other lipids in 
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micelles in the digestive track. The vitamin D taken up by intestinal enterocytes is 
incorporated into chylomicrons. The chylomicron is released by the enterocyte and 
is drained into the lymphatic circulation for systemic delivery. 
When vitamin D3 reaches the liver from either endogenous cutaneous 
production or from the diet, 25-hydroxylation of vitamin D occurs with the action of 
the liver enzyme 25-hydroxylases (25-OHase; encoded by the gene CYP27A1) to 
produce 25-hydroxyvitamin D3 (25(OH)D3), the main storage and circulating form 
for vitamin D. The 25(OH)D3 metabolite produced in the liver is attached to plasma 
vitamin D-binding protein (DBP)1 to then re-enter circulation. (P. H. Anderson, May, 
& Morris, 2003)  Once 25(OH)D3 reaches the kidney, it can be then 1α-hydroxylated 
by the enzyme 1α-hydroxylase (1α-OHase; encoded by the gene CYP27B1). This 
yields the hormonally active secosteroid 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), 
also called calcitriol.  Circulating 1,25(OH)2D3 can enter cells and bind to the vitamin 
D receptor (VDR), which activates this transcription factor to initiate the process of 
transcription of vitamin D-dependent genes by binding to a vitamin D response 
element in the promoter region of certain genes. In addition, it is now appreciated 
the 1α-hydroxylase CYP27B1 gene can also be expressed in non-renal cell types, 
which opens the possibility of local cellular control of 1,25(OH)2D3 exposure by 
coordinating the cellular expression of CYP27B1 to increase 1,25(OH)2D3 and 
CYP24A1 to decrease 1,25(OH)2D3. The possible complex paracrine and intracrine 
vitamin D pathways has provided an intriguing scientific basis for interpreting 
                                                        
1 The 25(OH)D3 metabolite bound to vitamin D-binding protein has a 
relatively long biological half-life and is stable in the blood for a significant periods 
of time (weeks) making it a more useful biomarker to assess overall vitamin D 
exposure.  
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possible effects of vitamin D exposure in a variety of chronic diseases, including 
cancer.  
1,25(OH)2D3 is inactivated by metabolism through a C-24 oxidation pathway. 
This biodegradation pathway is comprised of five enzymatic steps involving 24-
hydroxylase, (encoded by gene CYP24A1) which breaks down 1,25(OH)2D3 to a final  
water-soluble excretory product (calcitroic acid) that can be eliminated in the urine. 
Due to the presence of multiple vitamin D response elements in the promoter region 
of the CYP24A1 gene, the expression of CYP24A1 mRNA is highly responsive to 
1,25(OH)2D3  activation of the VDR. The response of CYP24A1 expression in a cell 
can thus be used as an index of 1,25(OH)2D3 activity in a cell.  (P. H. Anderson, May, 
& Morris, 2003)  
1.4 Vitamin D3: Calcemic Functions 
1,25(OH)2D3  is an important hormone in the regulation of serum calcium 
homeostasis and proper bone metabolism. 1,25(OH)2D3 helps to maintain serum 
calcium homeostasis by increasing the efficiency of intestinal calcium absorption in 
response to a drop in serum calcium. This calcemic effect of vitamin D effect occurs 
indirectly. A drop in serum calcium leads to increased secretion of parathyroid 
hormone (PTH) from the parathyroid gland, which then increases the renal 
synthesis of 1,25(OH)2D3 by increasing CYP27B1 (1α-hydroxylase) expression. 
Higher circulating 1,25(OH)2D3 concentrations help maintain calcium homeostasis 
by increasing vitamin D-dependent expression of calcium transport proteins, TRPV6 
and calbindin D, in the enterocyte, which promote increased calcium absorption. 
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This physiologic effect of 1,25(OH)2D3  in the intestine is complimented by the 
anticalcuric and bone-resorbing effect of PTH.  Once serum calcium levels are 
increased back to normal, PTH secretion is reduced and 1,25(OH)2D3  synthesis 
decreases. Elevated 1,25(OH)2D3 participates in a negative feedback signal on the 
parathyroid glands to suppress further synthesis of the PTH precursor, and vitamin 
D-induced CYP24A1 expression leads to increased breakdown of the vitamin D 
hormone.  
1.4.1 Vitamin D3: Non-calcemic Functions 
As mentioned above, the non-calcemic functions of 1,25(OH)2D3  may have 
important implications for carcinogenesis and include the regulation of cell 
proliferation and differentiation, hormone secretion, and immunomodulation. 
Vitamin D exerts most of its biological activities by binding to specific high-affinity 
vitamin D receptor (VDR). (Lopes et al., 2010) As the mediator of 1,25(OH)2D3 
action, the VDR is now widely recognized to be expressed in almost every tissue in 
the body; including: breast, brain, pituitary, stomach, skin, pancreas, central nervous 
system, and immune system. (Welsh et al., 2003)  The presence of VDRs in these 
diverse tissues suggests that these tissues are in some way vitamin D responsive, 
and the physiological effect of vitamin D is an active area of investigation.  
Research has shown that proliferation and differentiation of cancerous cells 
are affected by 1,25(OH)2D3 via an alteration of transcription of various cell cycle 
and other regulatory genes. For example, in human cell lines derived from normal 
breast tissue and breast cancers, 1,25(OH)2D3 and other VDR agonists can induce 
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cell cycle arrest, differentiation, and apoptosis. (Welsh et al., 2003)  Welsh and 
colleagues discovered that both HME (non-tumorigenic mammary epithelial cells) 
and MCF-7 (breast cancer cells) responded to increasing doses of 1,25(OH)2D3, 
which triggered cell growth arrest and apoptosis in comparison to non-treated cells. 
In a subsequent study, Welsh measured CYP24A1 gene expression (a marker of 
vitamin D status and biodegradation) in HME, MCF-7 and HKC-8 (proximal renal 
tubule cells), and found that after a 48 hour treatment with 100nM 1,25(OH)2D3, 
gene expression was increased by 60, 110, and 150% respectively. (Welsh, 2011)  
1.5 Molecular Mechanism of Vitamin D Genomic Activity 
Nuclear receptors (NR) are a class of proteins that are intracellular 
transcription factors that directly regulate gene expression, thereby controlling 
development, homeostasis and metabolism of an organism. (Nuclear Receptor 
Resource, 2011) The regulation of gene expression by NR usually only occur when a 
ligand is present. When a cognate ligand binds to its NR, it causes a conformational 
change in the receptor protein that activates the receptor, which can lead to an 
increased or decreased regulation of expression on certain genes.  (Seuter, 
Heikkinen, & Carlberg, 2013a)  The transcriptional outcome and dynamic balance of 
gene alterations of these nuclear receptors is determined by the ligand. The NR 
contains ligand-binding domains that will selectively bind lipid-soluble ligands, and 
DNA-binding domains that recognize and bind specific nucleotide sequences in 
target genes; thus inducing or repressing target gene promoters. (Welsh et al., 
2003).  
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The VDR is a member of the nuclear receptor family of proteins that acts as 
ligand-dependent transcription factors to modulate expression of specific genes in a 
tissue-specific manner. The 1,25(OH)2D3-VDR-dependent transcriptional activity is 
modulated through synergistic ligand-binding and dimerization with retinoic X 
receptor (RXR). This VDR-RXR receptor heterodimer is able to enter deep grooves in 
DNA and recognize vitamin D responsive elements in the promoter regions of 
vitamin D target genes. It is hypothesized that the 1,25(OH)2D3-VDR complex 
induces a program of gene expression that suppress cancer cell proliferation and 
stimulates differentiation in the normal mammary gland. This would mean that a 
dysregulation of VDR-mediated gene expression would lead to altered development 
and possible cell transformation leading to cell mutation. (Welsh et al., 2003) An 
important goal of VDR research is to identify the optimization of VDR signaling in 
the mammary gland to protect against breast cancer.  
Vitamin D exerts its biological activities by activating the VDR using a 
mechanism similar to that of other members of the steroid hormone superfamily. Its 
cellular actions are achieved by regulating the expression of the vitamin D 
responsive genes in the target tissues. (Chen & Deluca, 1995)  There are many genes 
that have been shown to be responsive to 1,25(OH)2D3; many of them play a direct 
role in calcium regulation and bone formation; osteocalcin, osteopontin, PTH, the 
hydroxylases CYP24A1 and the calbindin genes. The bone protein osteocalcin is 
upregulated by 1,25(OH)2D3, whereas PTH is down regulated. The calbindin-D9k 
gene is upregulated with increased calcium absorption and increased 1,25(OH)2D3 
expression. (Jones, Tighilet, Tran, & Huntsman, 1998)   
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The 24-hydroxylase gene CYP24A1 is an immediate target gene of VDR 
expression, it is one of the most highly regulated genes that respond to 1,25(OH)2D3, 
and 1,25(OH)2D3 is thought to be the sole physiological inducer of 24-hydroxylase 
activity. (Johnson, Chung, & Trump, 2010)  Increased expression of the CYP24 
enzyme initiates a negative feedback loop and leads to increased catabolism and 
inactivation of 1,25(OH)2D3. Studies have clearly demonstrated that the 24-
hydroxylase gene (CYP24A1) is regulated at the transcriptional level by 
1,25(OH)2D3 . With the presence of the 1,25(OH)2D3 ligand, it is a sensitive marker 
for VDR function because its promoter region contains multiple vitamin D response 
elements (VDRE). (Chen & Deluca, 1995)   
Shinki and colleagues (Shinki et al., 1992) investigated tumor-derived 
endothelial cells, TDEC, and Martigel plugs, MDEC, by exposing them to 1,25-
dihydroxycholecalciferol and then measuring the mRNA of CYP24A1. The analysis 
found that there was no induced expression of the VDR signaling pathway in the 
tumor-derived cell study, and the normal MDEC showed the expected level of 
CYP24A1 expression. This shows that untreated tumor cells can epigenetically alter 
gene expression, and thus inhibit expression of VDR. Combating the tumor’s 
epigenetic change and induce CYP24A1 expression could increased the benefits 
found with calcitriol-mediated therapies.  
1.6 Epigenetic Modulation of Gene Expression  
C. H. Waddington first introduced the concept of epigenetics in 1939 as a way 
to name the “causal interactions between genes and their products, which bring the 
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phenotype into being.” (Esteller, 2003) Currently the term epigenetics refers to the 
modification in gene expression caused by heritable, and potentially reversible, 
alterations in chromatin structure and/or DNA methylation without changes in the 
DNA sequence. (Gerhaeuser, 2012)  
The DNA nucleotide sequences are the genetic instructions that are used to 
develop and regulate the functioning of all cell processes. Epigenetics is the study of 
changes in the gene expression or cellular phenotype caused by mechanisms other 
than changes to the underlying DNA sequence. It refers to the functionally relevant 
modifications to the genome that do not involve a change in the nucleotide 
sequence. Examples of such modifications are DNA methylation, histone protein 
modifications and microRNA expression. These changes remain through cell 
division for the remainder of the cell’s life, and may also last for multiple 
generations. These epigenetic changes can be inherited by daughter cells, thus 
having the potential to correct altered gene expression patterns that have been 
established as a consequence of environmental stimuli. (Gerhaeuser, 2012)  
1.6.1 Histone Modification 
Histone modification is defined as, post-translational modification at the N-
terminal histone tails of histone proteins; acetylation and methylation are the two 
most recognized mechanisms. These contribute to epigenetic regulation of gene 
expression, genomic stability, DNA damage response and cell cycle checkpoint 
integrity. (Gerhaeuser, 2012) Histone acetylation and deacetylation are mediated by 
an interplay of enzymes that activate and deactivate the paired processes. Histone 
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acetylation, by histone acetyltransferase (HAT), acetylates the lysine residues to 
decrease compaction, in part due to the weakened charge attraction between the 
DNA and histone proteins; this increases gene activation and transcription. While 
histone deacetylase (HDAC) works to remove that acetyl group from the lysine and 
increase compaction and decrease transcription.  
Perturbation of the balance between histone acetylation and deacetylation is 
considered a key factor in cancer development, and an overexpression of HDAC is a 
characteristic often seen in cancer cells. Reversible acetylation of histones and non-
histone proteins has been shown to affect cell metabolism and other cellular 
processes, thus can be targeted by inhibitors of histone deacetylases, which will 
increase acetylation and can cause the chromatin structure to remain open and 
available for transcription of important anti-cancer genes, such as those involved in 
apoptosis; thus, limiting one of the cancer cell’s self-preservation mechanisms.  
1.7 Histone Deacetylase Inhibitors (HDACI) 
As HDAC are associated with transcriptional repression  (Christensen & 
Marsit, 2011) , histone deacetylase inhibitors (HDACI) are a class of compounds that 
interfere with the function of HDAC and have been known to induce 
hyperacetylation, which affects gene expression by modulating the chromatin 
structure.  (Dashwood & Ho, 2007; Davis & Ross, 2007)  Numerous data have shown 
that a main characteristic of cancer is global hypomethylation and hypermethylation 
of specific DNA regions, mainly within the promoters of tumor suppressor genes. 
The increase in promoter DNA methylation was reported as a common mechanism 
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of tumor suppressor gene silencing observed in many types of cancers.  (Stefanska, 
Karlic, Varga, Fabianowska-Majewska, & Haslberger, 2012)  
A working hypothesis is that in the presence of HDAC, a cancer cells 
chromatin interactions are kept in a constrained state. HDACI enable the net 
transfer of acetyl groups to lysine tails in histones, thereby loosening the 
interactions with DNA and facilitating transcription factor access and gene 
activation. (Dashwood & Ho, 2007) Enabling increased transcription and activation 
of important tumor suppressor genes via HDACI, could yield promising treatment 
outcomes for cancer patients.  
The classical HDACI that have been recognized are as follows in decreasing 
order of potency; hydroxamic acids, such as trichostatin A (TSA); cyclic 
tetrapeptides, such as trapoxin B; benzamides; electrophilic ketones; and aliphatic 
acid compounds, such as phenylbutyrate and valproic acid. 
1.7.1 Trichostatin A (TSA) 
Trichostatin A (7-(4-(dimethylamino)phenyl)-N-hydroxy-4,6-dimethyl-7-
oxohepta-2,4-dienamide) is the most potent HDACI chemical agent that has been 
discovered thus far. It is an organic compound that was originally used as an 
antifungal antibiotic. It has now been discovered as a potent anti-proliferative agent 
from its ability to alter gene expression. (Yoshida, 2007) It has a large spectrum of 
epigenetic activities; promotes the expression of the apoptosis-related genes, 
induces cell differentiation thus acting to mature some of the de-differentiated cells 
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found in tumors and acts as an anti-cancer drug by slowing down cancer cell 
survival and progression.  (Kim, Kang, Na, & Lee, 2010; Meadows, 2012)   
TSA has been found to be effective at nanomolar concentrations, among a 
variety of human and animal cancer cells. Table 1.1 identifies experimental 
parameters tested in TSA oncology studies. Various human breast and prostate 
cancer cells show decreased protein stability as well as increased CYP24A1 
expression with TSA treatments ranging from 3 to 400 nM.  (Drzewiecka & 
Jagodzinski, 2012a; Kim, Kang, Na, & Lee, 2010; Luo et al., 2010)  
1.7.2 Sulforaphane (SFN) 
Sulforaphane (1-Isothiocyanato-4-methylsulfinylbutane) is a newly 
researched bioactive food compound that shows promising HDACI properties. SFN 
is predominantly found in Brassica vegetables; which are a genus of plants from the 
mustard family that include cruciferous vegetables (broccoli, cauliflower, water 
cress, and bok choy), cabbages and mustard greens. Sulforaphane is a molecule 
within the isothiocyanate group of organosulfur compounds. It is produced when 
the enzyme myrosinase transforms glucoraphanin into sulforaphane upon damage 
to the plant (such as mechanical chewing), which allows the two compounds to mix 
and react.  
Further research into sulforaphane has shown that it exhibits similar HDACI 
activity as TSA, but at a lower intensity. SFN acts as a weak ligand for histone 
deacetylase, and has been shown to cause inhibition of cancer cell proliferation and 
stimulation of apoptosis. (Dashwood & Ho, 2007)  SFN shows promise as a co-
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cancer-treatment and especially for cancer prevention because it is so bioavailable 
from food sources, just 1¼-cup broccoli sprouts metabolizes to a 5μmol/L SFN level 
in breast tissue. (Li et al., 2010a)   
Table 1.2 provides information on the experimental parameters in cancer cell 
research with SFN. In a human hepatoma cell line, a moderate dose of 1 to 10μM 
SFN had a dose dependent response of increasing mRNA expression of the CYP1A1 
gene.  (Anwar-Mohamed & El-Kadi, 2009)  As well, a 1 to 20μM dose of SFN in 
human colorectal cells showed significant increases in human β-defensin-2.  
(Schwab et al., 2008)  
1.7.3 Epigenetic Modulation of Vitamin D Mediated Genes by HDACI 
There have been a variety of studies that demonstrate the VDR modulating 
antiproliferative effects of 1,25(OH)2D3 can be greatly enhanced with a combination 
treatment of HDACI; as illustrated in Table 1.3 with 1,25(OH)2D3 and TSA co-
treatments. Banwell and colleagues (C. Banwell, O'Neill, Uskokovic, & Campbell, 
2004) identified a class of breast cancer cells that show resistance to 1,25(OH)2D3, 
thus correlating to reduced VDR activity and increased nuclear co-receptors (NCoR) 
activity. NCoR will maintain chromatin in a transcriptionally repressed state; NCoRs 
are often overexpressed in several types of cancer. Recent research is showing that 
increasing VDR signaling will epigenetically block NCoR activity and thus maintain 
VDR gene expression. (Deeb, Trump, & Johnson, 2007)  Banwell and colleagues 
examined the MDA-MB-231 cell line that is resistant to antiproliferative 
1,25(OH)2D3 action. With a solo treatment of 1nM 1,25(OH)2D3, these cells exhibited 
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an altered expression ratio of 0.1 fold reduction in VDR and 1.7 fold increase in 
NCoR1, in comparison to the MCF-12A (non-malignant) cell line which shows 
normal 1,25(OH)2D3 responsiveness. With a co-treatment of 15nM TSA, the MDA-
MB231 cell line previously non-responsive to vitamin D, showed drastic changes in 
antiproliferative effects; there was a 60% inhibition of colony formation, compared 
to no inhibition with only 1nM 1,25(OH)2D3 and a mere 30% inhibition with 15nM 
TSA. Concluding that the combination treatments of 1,25(OH)2D3 and TSA can 
significantly increase breast cancer cells reception to the antiproliferative effects of 
vitamin D.  
Banwell and colleague’s follow-up study (C. Banwell et al., 2006) looked 
more closely at the epigenetic changes with combination treatments of 1,25(OH)2D3 
and TSA. She examined CYP24A1 gene expression as well as the antiproliferative 
genes GADD45α and VDUP-1. She found that by increasing the dosage of 
1,25(OH)2D3 to 100nM, and maintaining the same TSA treatment of 15nM, there was 
a 15 fold increase in CYP24A1 expression, and about a 2 fold increase in the other 
two antiproliferative genes as compared to the solo 1,25(OH)2D3 treatment. Similar 
results have also been seen with human prostate cells DU-145. The same dosages as 
the Banwell’s study yielded a 2-fold increase in CYP24A1 expression. (Rashid et al., 
2001) 
1.8 Vitamin D Effects on MCF-7 Cells 
Despite the research, the antiproliferative effect of vitamin D on cancer cells 
is still controversial. Research with breast cancer cells has shown that there are a 
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variety of characteristics between cell types, making the results varied and non-
generalizable. Many researchers have utilized the unique properties of the MCF-7 
cell when investigating vitamin D and HDACI with breast cancer. It is a mammary 
gland cell from a breast adenocarcinoma derived at a metastatic site, from a 69-
year-old Caucasian female. (ATCC, 2013) MCF-7 have been found to have a specific 
calcitonin receptor and calcitonin-responsive adenylate cyclase, as well as have a 
specific macromolecular cytosol receptor for the vitamin D hormone, 1,25(OH)2D3  
(Levenson & Jordan, 1997) , making them estrogen receptor positive (ER+) cells and 
quite responsive to 1,25(OH)2D3. (C. Banwell et al., 2006) The laboratory work on 
the systematic dissection of hormone action that lead to significant progress in 
breast cancer treatment was made possible by the MCF-7 cells hormone 
responsiveness.  
An intensely studied model of cancer/vitamin D research is that increasing 
vitamin D status in breast cancer MCF-7 cells as protective against cancerous 
mutations, which lead to cancer cell proliferation and malignancy. (Colston, 2008) 
TSA has been researched to show an increase in vitamin D responsiveness in MCF-7 
cells, but SFN, a bioactive food component, has had little research and may have 
protective capabilities as well. Therefore, in this study we propose to investigate the 
effects of 1,25(OH)2D3 on vitamin D dependent gene expression in MCF-7 human 
breast cancer cells in the presence of the HDACI, TSA and SFN.  
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Table 1.1 TSA Study Experimental Parameters 
 
Cell 
Type 
TSA 
Dosage 
Exposure 
Time 
Outcome 
Measure 
Effects 
Compared to 
Control 
 
Reference 
Human 
Breast 
Cancer 
Cells 
MCF-7 
3nM 
30nM 
48 hours Cellular 
contents of 
PLCγ1 
 
Transcription 
and protein 
levels were 
reduced four 
fold. 
 
(Drzewiecka 
& 
Jagodzinski, 
2012b)  
Human 
Breast 
Cancer 
T47D 
1μM 1 to 3 
hours 
Protein 
stability of 
ERα and p300 
proteins, to 
signify 
changes in 
acetylation 
ERα and p300 
protein stability 
increased by 
30%, in a dose 
dependent 
manner. 
 
 (Kim, Kang, 
Na, & Lee, 
2010)  
Human 
Prostate 
Cancer 
Cells 
DU145 
LNCaP 
PC3 
 
50nM 
100nM 
200nM 
300nM 
400nM 
8 hours Changes in 
CYP24A1 gene 
expression 
CYP24A1 gene 
expression was 
increased by 
1.6-4.0 fold 
(Luo et al., 
2010) 
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Table 1.2 SFN Study Experimental Parameters 
 
Cell Type SFN 
Dosage 
Exposure 
Time 
Outcome 
Measure 
Effects 
Compared to 
Control 
Reference 
Human 
Embryonic 
Kidney 
Cells  
HEK293 
SFN 
5μM +  
TSA 
100ng/
mL 
48 hours HDAC activity HDAC activity 
was depressed:  
SFN + TSA 
(60%) > SFN 
(30%) > TSA 
(25%) 
 (M. C. 
Myzak, 
Tong, 
Dashwood, 
Dashwood, 
& Ho, 
2007)  
Human 
Prostate 
Cancer 
Cells 
LNCaP 
C4-2 
10μM 
20μM 
40μM 
 
24 hours Levels of 
Androgen 
Receptor (AR)  
and 
Prostate 
Specific 
Antigen (PSA) 
AR mRNA 
decreased by 
40% to 80% in 
both cell lines. 
PSA protein 
levels decreased 
in both cell lines. 
 
 (Kim & 
Singh, 
2009)  
Human 
Hepatoma 
Cells 
HepG2 
 
1.0μM 
2.5μM 
5.0μM 
10μM 
6 hours CYP1A1 mRNA 
expression 
 
Dose-dependent 
increased mRNA 
expression 
1.0μM = 2.2 fold 
2.5μM = 2.8 fold 
5.0μM = 3.8 fold 
10μM = 3.6 fold 
 
 (Anwar-
Mohamed 
& El-Kadi, 
2009)  
Human 
Colorectal 
Cancer 
Cells 
Caco-2 
HT-29 
SW480 
1μM 
5μM 
10μM 
20μM 
24 hours 
and 
48 hours 
Human β-
defensin-2  
(HBD-2) gene 
expression 
At 24 hours 
there was a 1.6 
fold increased in 
HBD-2 
expression with 
20μM SFN. 
At 48 hours 
there was a 2-
fold increase.  
 
(Schwab et 
al., 2008b) 
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Table 1.3 Modulation of Vitamin D-mediated Gene Expression by HDACI 
 
Cell Type HDACI 
Dosage 
Exposure 
Time 
Outcome 
Measure 
Effects of Co- 
Treatment 
Compared to 
1,25(OH)2D3  
Reference 
1,25(OH)2D3 
Dosage  
Human 
Breast 
Cancer 
cells 
MDA-MB-
231 
15 nM(TSA) 36 hours Colony 
Formation 
60% 
inhibition of 
colony 
formation 
 (C. 
Banwell, 
O'Neill, 
Uskokovic, 
& 
Campbell, 
2004)  
1 nM 
Human 
Prostate 
Cancer 
cells 
DU-145 
15 nM (TSA) 
 
72 hours Change in 
activity of 
mRNA 
expression: 
CYP24A1 and 
p21 
CYP24A1 
expression 
increased 2.5 
fold.  
p21 increased 
1 fold. 
(Rashid et 
al., 2001) 
100 nM 
Human 
Leukemia 
Cells 
THP-1 
300 nM 
(TSA) 
 
150 
minutes 
Transcription-
al response of 
genes 
HBEGF 
DUSP10 
80% increase   (Seuter, 
Heikkinen, 
& Carlberg, 
2013a)  100 nM 
Human 
Breast 
Cancer 
Cells 
T-47D 
ZR-75-1 
MCF-7 
MDA-MB-
231 
15 nM (TSA) 
 
12 hours Changes in  
CYP24A1,  
GADD45α and 
VDUP-1 gene 
expression 
CYP24 
increased 15 
fold. 
GADD45α 
increased 2.4 
fold. VDUP-1 
increased 2.1 
fold. 
(C. Banwell 
et al., 2006) 
100 nM 
Human 
Breast 
Cancer 
cells 
MCF-7 
MDA-
MB453 
15 nM (TSA) 
 
3 hours Fold change of 
mRNA 
p18, p19, p21, 
p27 
MCF-7 
showed 
reduced p18 
and p19 
mRNA. 
MDA-MB453 
showed 
reduction in 
p21 mRNA 
only.  
(Malinen et 
al., 2008) 
10 nM 
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CHAPTER 2 
PURPOSE OF STUDY 
2.1. Overview 
 Many studies have investigated the effects of trichostatin A (TSA), a potent 
histone deacetylase inhibitor (HDACI), on vitamin D-dependent gene 
responsiveness in various cancer cell lines; for example, human prostate cancer DU-
145 (Rashid et al., 2001), human leukemia cells THP-1 (Seuter, Heikkinen, & 
Carlberg, 2013b)  and multiple breast cancer cells lines MDA-MB-231, T-47D, ZR-75-
1 and MCF-7  (C. M. Banwell, Singh, Stewart, Uskokovic, & Campbell, 2003; C. 
Banwell et al., 2006; Malinen et al., 2008) . Sulforaphane (SFN) is a bioactive food 
component that has HDACI activity. However, there is a gap in our knowledge 
concerning the effects of SFN on vitamin D-mediated gene expression in breast 
cancer cells. This lack of knowledge is a problem because we are potentially missing 
an important opportunity to utilize a natural food component such as SFN as an 
epigenetic agent to alter breast cancer cell function, including the possibility of 
further enhancing vitamin D effects as an anti-cancer therapy. In addition, a 
stronger scientific understanding of the effects of SFN on the expression of certain 
vitamin D-dependent genes in breast cancer cells could encourage a new direction 
of research combining nutrients and bioactive food components with applications to 
other organs susceptible to cancer, such as the colon and prostate.  
The main objective of this study is to better understand to what extent the 
HDACI TSA and the bioactive food component SFN can modulate vitamin D action in 
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the MCF-7 cell line.  Our central hypothesis is that TSA and SFN will increase cellular 
vitamin D responsiveness, as measured by increased expression of specific vitamin 
D-induced genes. The hypotheses listed below are based upon the strong support in 
the published literature showing that there is an increased expression of vitamin D-
induced genes following treatment with a HDACI. 
2.2. Specific Aims and Hypotheses 
• Experiment 1: Effect of TSA on Vitamin D-Induced Gene Expression 
Specific Aim: Determine to what extent TSA treatment affects vitamin D-induced 
CYP24A1, TRPV6 and VDR mRNA expression in MCF-7 cells.  
Hypothesis: Combination treatment of 1,25(OH)2D3 and TSA will increase vitamin D-
responsive gene expression in MCF-7 cells to a greater extent than 1,25(OH)2D3 
alone.  
• Experiment 2: Effect of SFN & TSA on Vitamin D-Induced Gene 
Expression 
Specific Aim: Determine to what extent a SFN or TSA treatment affects vitamin D-
induced CYP24A1, CYP27B1, TRPV6 and VDR mRNA expression in MCF-7 cells.  
Hypothesis: Combination treatment of 1,25(OH)2D3 and SFN or TSA will increase 
vitamin D-responsive gene expression in MCF-7 cells to a greater extent than 
1,25(OH)2D3 alone.  
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2.3. Significance 
 Studies in breast cancer cell culture models and in vivo animal breast cancer 
models support an anti-cancer effect of 1,25(OH)2D3 treatment. However, systemic 
treatment with the vitamin D hormone elicits a calcemic response that can lead to 
the development of hypercalcemia, which limits the therapeutic window of this 
compound.  Thus, the development of treatments that could enhance the anti-cancer 
effects of endogenous vitamin D by increasing intracellular availability/activity of 
1,25(OH)2D3 could be therapeutically useful in treatment, or as a possible low-risk 
chemo-preventative strategy.  
The contribution of these research studies is twofold; first, we characterized 
the influence of 1,25(OH)2D3 alone on genes potentially responsive to vitamin D 
(CYP24A1, TRPV6), or part of the a network of genes involved in vitamin D 
metabolism (VDR, CYP27B1, CYP24A1) in MCF-7 human breast cancer cells, and 
second, we determined the extent to which co-treatment with HDACI compounds, 
TSA and SFN, can increase  vitamin-D induced gene expression.  
These contributions are significant because they indicate to what extent 
these two HDACI influence vitamin D response. These findings could have future 
implications in cancer treatment and prevention, as well as encouraging further 
research into possible chemotherapy treatments for certain cancers utilizing HDACI.   
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2.4. Limitations 
 Cell culture models are useful for identifying possible molecular changes 
induced by various treatments. However, caution must be used when extrapolating 
the findings from these experiments performed in cell culture directly to humans. 
Human physiology is far more complex than that of cells grown in a dish.  Thus, 
findings from this type of study will best be used to aid in hypothesis formation 
related to how these processes may function in humans, rather than as a basis for 
clinical recommendations and practices. Our experimental MCF-7 breast cancer cell 
model represents only one of the many approaches that could be utilized to study 
the interactions between 1,25-dihydroxyvitamin D and HDACI, and thus the 
translatability of our findings to other situations will need to be assessed.  
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CHAPTER 3 
EXPERIMENTAL DESIGN AND METHODS 
3.1 Experimental Design 
This study investigated the effects of a 24h co-treatment of 10 nmol/L 
1,25(OH)2D3 and histone deacetylase inhibitors (TSA 1 µmol/L or SFN 20 µmol/L) 
on CYP24A1, CYP27B1, TRPV6 and VDR mRNA in MCF-7 cells, a breast cancer cell 
culture model known to  respond to vitamin D.  (Levenson & Jordan, 1997)  
Relative gene expression levels were determined by real time qPCR of mRNA 
following incubation of cells with 1,25(OH)2D3 alone or in combination with TSA in 
Experiment 1 and for Experiment 2, and with SFN in Experiment 2. TSA, SFN, and 
1,25(OH)2D3 treatment concentration and incubation times were chosen in 
accordance with published literature values. (C. Banwell, O'Neill, Uskokovic, & 
Campbell, 2004; Malinen et al., 2008; Welsh, 2011) Based on the known role of TSA 
and SFN as a HDACI, we expected that vitamin D-mediated gene expression of 
CYP24A1, CYP27B1, TRPV6 and VDR would increase in the presence of either 
HDACI.  
3.2  Methods 
3.2.1 Cell Culture  
Human breast cancer cells, MCF-7 (kindly provided by Dr. H. Xiao’s Lab, Food 
Science Dept., UMass) were grown in 6-well culture plates to 100% confluence 
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(about 96 - 120 hours), using MEM growth media (89% MEM (Gibco), 10% fetal 
bovine serum, and 1% penicillin/streptomycin). Cells were incubated at 37°C with 
5% CO2. At the completion of the experiment, cells were harvested in Trizol and 
RNA was subsequently extracted, quantified and cDNA synthesized.  
3.2.2 Experiment 1: Effect of TSA on Vitamin D-Induced Gene Expression  
Upon reaching 100% confluence (96 hours), the MCF-7 cells were treated 
with various combinations of TSA and 1,25(OH)2D3.  A total of four 6-well plates 
were used with four different treatments (n=6 wells/treatment; Table 3.1), yielding 
a total of 24 samples. The first treatment was the vehicle-treated control, which 
contained an equal volume of ethanol vehicle and was used as the reference 
treatment in the statistical analysis. The second treatment was 1μmol/L TSA 
(Sigma-Aldrich, St. Louis, MO) dissolved in ethanol and was used to detect the effect of 
the HDACI alone. The third treatment was 10nmol/L 1,25(OH)2D3 (Enzo Life Sciences, 
Plymouth Meeting, PA) dissolved in ethanol. The final treatment was a co-treatment of 
10nmol/L 1,25(OH)2D3 and 1μmol/L TSA. The cells were incubated with the various 
treatments for 24 hours before being harvested. Treatment calculations are found in 
Appendix A.  
Table 3.1 Experiment 1 Samples and Treatments 
 
Sample Number Treatment 
1-6 Control (ethanol) 
7-12 1μmol/L TSA 
13-18 10nmol/L 1,25(OH)2D3 
19-24 10nmol/L 1,25(OH)2D3 + 1μmol/L TSA 
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3.2.3 Experiment 2: Effect of SFN & TSA on Vitamin D-Induced Gene Expression  
In the second experiment, MCF-7 cells were grown in 6-well dishes to 100% 
confluence and treated 120 hours after sub-culturing with one of 5 possible 
treatments for 24h prior to harvesting the cells.  The treatment scheme is shown in 
Table 3.2 and is similar to Experiment 1 with the addition of a SFN (Sigma-Aldrich, 
St. Louis, MO ; 20 µmol/L) and SFN plus 1,25(OH)2D3  treatment groups.  Half of the 
wells were treated with 10nmol/L 1,25(OH)2D3 (Enzo Life Sciences, Plymouth 
Meeting, PA). Treatment calculations are found in Appendix A.  
Table 3.2 Experiment 2 Samples and Treatments 
 
Sample Number Treatment 
1-4 Control 
5 & 6 1μmol/L TSA 
7-12 20μmol/L SFN 
13-16 10nmol/L 1,25(OH)2D3  
17 & 18 10nmol/L 1,25(OH)2D3 + 1μmol/L TSA 
19-24 10nmol/L 1,25(OH)2D3 + 20μmol/L SFN SFN 
3.3 Gene Expression Analysis 
3.3.1 RNA Isolation and Quantification 
After the 24-hour treatment period, total cellular RNA was harvested.  The 
media was aspirated from the treatment wells, the cells were washed once with a 
PBS solution, and the cells where then treated with 750μL TRIzol LS reagent (Life 
Technologies) and scraped from the plate and homogenized. The TRIzol-treated cell 
homogenate was stored at -80°C in 1.5mL plastic Eppendorf tubes until used for 
mRNA isolation.  
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To isolate the total RNA, 150μL chloroform reagent was added to each 
homogenate, mixed and centrifuged to separate the organic and aqueous phases. 
The aqueous layer was then removed with a pipet and transferred into a new 1.5mL 
Eppendorf tube, where 500μL isopropanol was added to precipitate the RNA. The 
precipitated RNA was washed once with 1 mL of 75% ethanol (made with Milli-Q 
water). Then, 40μL DEPC-treated water was added to each sample and incubated for 
ten minutes at 56°C in order to make the RNA soluble. RNA samples were quantified 
by uv/vis spectrophotometry, as follows: 2μL of the RNA sample in DEPC-treated 
water was diluted in 498μL Milli-Q water, and then placed in a quartz cuvette and 
absorbance was measured at λ=260nm.   
cDNA was prepared from the RNA using reverse transcriptase in the 
SuperScript III First-Strand Synthesis System and oligo dT primer (Life 
Technologies, Grand Island, NY) following the  manufacturer’s instructions.  cDNA 
was measured at λ=260. Detailed protocol instructions and calculations are found in 
Appendix B.  
3.3.2 Real Time PCR 
For all experiments, mRNA expression was measured by Real Time PCR 
using a StepOnePlus Real-Time PCR System (Applied Biosystems, Foster City, CA). 
Reactions consisted of MilliQ water, 200ng of cDNA, 2x TaqMan Gene Expression 
Master Mix (Applied Biosystems, Foster City, CA), 20x TaqMan Gene Expression 
assays for GAPDH (housekeeping gene) and either CYP24A1, CYP27B1, TRPV6 or 
VDR (Applied Biosystems, Foster City, CA). Cycle number (CT) measurements  were 
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normalized (ΔCT) to GAPDH CT expression by subtracting the CT of GAPDH 
expression from each target gene of interest (GOI) (ΔCT= GOICt - GAPDHCt). A 
detailed protocol is found in Appendix B.  
3.4 Statistical Analysis 
Derived ΔCT measurements (GOI mRNA corrected by GAPDH mRNA 
expression) were transcribed to Graph Pad Prism 5.0 tables for statistical analysis. 
Comparisons among treatment means were done by using the comparative CT 
method. In Experiment 1 and 2, all ΔCT data were initially checked for possible 
outliers using the Grubb’s test in GraphPad Prism. One data point in the combined 
TSA and vitamin D treatment group in Experiment 1 was identified as being 
statistically significant and it was excluded.  Statistical significance among treatment 
groups in each experiment was carried out on ΔCT measurements and tested by a 
one-way ANOVA with Bonferroni’s post-hoc test for specific individual pair-wise 
treatment mean comparisons. The alpha level for statistical significance was set at 
p<0.05. For ease of interpretation and for graphical illustration, data were 
converted into relative fold-expression with the vehicle control treatment set to a 
value of 1, using the ΔΔCT method, in which ΔΔCT is calculated as follows: ΔΔCT=(ΔCT 
Experimental Treatment –ΔCT Vehicle Control Treatment) and the relative fold change in expression 
is calculated as 2-(ΔΔCt). Data are presented in the text and figures as mean ± standard 
error of the mean (SEM).  
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CHAPTER 4 
RESULTS 
4.1  Experiment 1: Effect of TSA on Vitamin D-Induced Gene Expression 
Previous studies have found that a co-treatment of various breast cancer cell 
lines with 1,25(OH)2D3 and the histone deacetylase inhibitor (HDACI) trichostatin A 
(TSA) had an antiproliferative effects. (C. Banwell, O'Neill, Uskokovic, & Campbell, 
2004; C. Banwell et al., 2006; Malinen et al., 2008)  We hypothesized that a co-
treatment of 1,25(OH)2D3 with the HDACI TSA would increase vitamin D-dependent 
CYP24A1, TRPV6 and VDR gene expression in MCF-7 cells.  
4.1.1 VDR mRNA 
Treatment of MCF-7 cells for 24 h with the histone deacetylase inhibitor TSA 
(Figure 4.1) caused a significant 11-fold increase in VDR mRNA compared to 
vehicle-treated control cells (11.2 ±4.4 vs. 1.0 ± 0.3, mean ± SEM, n=6 and n=5, 
respectively). Treatment with a 10nmol/L dose 1,25(OH)2D3 alone had no effect (0.8 
± 0.4, n=6) on VDR gene expression.  VDR expression was significantly increased in 
cells treated with both 1,25(OH)2D3 and TSA (2.3 ± 0.1, n=5) compared to 
1,25(OH)2D3 treatment alone.   
4.1.2  CYP24A1 mRNA 
Treatment with TSA alone (Figure 4.2) increased CYP24A1 mRNA 10-fold 
compared to controls (10.0 ± 3.2 vs. 1.0 ± 0.7, n=5 and n=6, respectively).   
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1,25(OH)2D3 treatment  increased CYP24A1 gene expression by 80-fold (80.0 ± 15.8, 
n=6) compared to controls. Although there was an apparent doubling of CYP24A1 
mRNA between the 1,25(OH)2D3 only treatment and the 1,25(OH)2D3 and TSA 
treatment (163.0 ± 18.0, n=6), this difference was not statistically significant.  
4.1.3 TRPV6 mRNA 
TRPV6 gene expression was only evident in very few samples in Experiment 
1 negating an assessment of treatment effects on this gene in MCF-7 cells. 
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Figure 4.1 Experiment 1: Effect of TSA on VDR Gene Expression 
Mean ± SEM fold change of VDR mRNA in comparison to a control, at the value of 1.  
Statistical significance notation: a= p<0.05 vs. control, b= p<0.05 vitamin D 
compared to vitamin D & TSA.  
 
 
Figure 4.2 Experiment 1: Effect of TSA on CYP24A1 Gene Expression 
Mean ± SEM fold change of CYP24A1 mRNA in comparison to a control, at the value 
of 1.  Statistical significance notation: a= p<0.05 vs. control. Note difference in scale 
on y-axis.  
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4.2  Experiment #2: Effect of SFN & TSA on Vitamin D-Induced Gene Expression 
There is limited previous research on the effects of sulforaphane (SFN) on 
gene expression in MCF-7 breast cancer cells. Some experiments have shown that 
solo treatment with SFN can decrease histone deacetylase (HDAC) activity, 
supporting a role of SFN as a possible histone deacetylase inhibitor (HDACI). (M. 
Myzak, Karplus, Chung, & Dashwood, 2004) However, the effects of a co-treatment 
of 1,25(OH)2D3 and SFN in MCF-7 cells had not yet been investigated. We 
hypothesized that a co-treatment of 1,25(OH)2D3 with the HDACI, SFN, would 
increase vitamin D-dependent VDR, CYP24A1, CYP27B1, and TRPV6 gene 
expression in MCF-7 cells. We tested this hypothesis by growing MCF-7 cells to 
100% confluence and treated them for 24 hours with either 10nmol/L 1,25(OH)2D3, 
20μmol/L SFN or a combination treatment. We also included treatment with 
1μmol/L TSA alone and in combination with 1,25(OH)2D3 to replicate the findings in 
Experiment 1.  
4.2.1 VDR mRNA  
Similar to what was observed in Experiment 1, treatment of MCF-7 cells in 
Experiment 2 with TSA alone (Figure 4.3) for 24h increased VDR mRNA compared 
to vehicle-treated controls (12.6 ± 4.2 vs. 1.0 ± 0.2, n=2 and n=4, respectively). In 
contrast to the positive effect of the histone deacetylase inhibitor TSA on VDR 
mRNA, treatment with the histone deacetylase inhibitor SFN (20 µmol/L for 24h) 
had no effect (1.1 ± 0.3, n=6) on VDR mRNA compared to controls. However, in 
contrast to the lack of effect of 1,25(OH)2D3 on VDR mRNA we observed in 
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Experiment 1, in this experiment 10nmol/L 1,25(OH)2D3 had a positive effect on 
VDR mRNA (6.3 ± 1.8).  VDR mRNA expression in the combination treatment of 
1,25(OH)2D3 and TSA was 22.6 ± 15 (n=2), but this apparent increase in VDR mRNA 
was not statistically significant, which reflects the low number of samples tested and 
the marked variation observed in VDR mRNA between these two samples (37.6 and 
7.6). Unexpectedly, we observed that VDR mRNA was lower with SFN and 
1,25(OH)2D3 combination treatment than when 1,25(OH)2D3 was given alone (1.4 
±0.3 vs 6.3 ± 15.0).   
4.2.2 CYP24A1 mRNA  
Compared to vehicle-treated control cells (1.0 ± 0.0, n=4), an increase in VDR 
mRNA was found after treatment with either TSA (14.0 ± 0.9, n=2), SFN (18.9 ± 1.6, 
n=2), or 1,25(OH)2D3 (12,746 ± 5,597) alone (Figure 4.4). The positive effect of TSA 
and 1,25(OH)2D3 on CYP24A1 mRNA is consistent with what was observed 
previously in Experiment 1. The combination treatment of 1,25(OH)2D3 with either 
SFN (7,603 ± 2,245) or TSA (18,393 ± 13,678, n=2), however, caused no further 
significant increase in CYP24A1 mRNA compared to 1,25(OH)2D3 alone.   
4.2.3 CYP27B1 mRNA 
Treatment with TSA (0.9 ± 0.1, n=4) or SFN (0.6 ± 0.0) alone had no effect on 
CYP27B1 expression (Figure 4.5). CYP27B1 mRNA was increased in 1,25(OH)2D3 
treated cells (6.8 ± 5.1, n= 4) compared to controls (1.0 ± 0.0, n=4). Compared to 
1,25(OH)2D3-treated cells, co-treatment with 1,25(OH)2D3 and TSA had no further 
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effect (6.4 ± 5.2, n=2), while SFN treatment with 1,25(OH)2D3 (2.0 ± 0.7, n= 5) 
significantly reduced the positive effects of 1,25(OH)2D3 on CYP27B1 mRNA.  
4.2.4 TRPV6 mRNA 
As observed in Experiment 1, TRPV6 gene expression was also only evident 
in very few samples in Experiment 2, negating an assessment of treatment effects on 
this gene in MCF-7 cells.  
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Figure 4.3 Experiment 2: Effect of SFN and TSA on VDR mRNA 
Mean ± SEM fold change of VDR mRNA in comparison to vehicle-treated control, at 
the value of 1.  Statistical significance notation: a= p<0.05 vs. control, b= p<0.05 
vitamin D alone vs. vitamin D and HDACI.  
 
 
Figure 4.4 Experiment 2: Effect of SFN and TSA on CYP24A1 mRNA 
Mean ± SEM fold change of CYP24A1 mRNA in comparison to a control, at the value 
of 1.  Statistical significance notation: a= p<0.05 vs. control. Note difference in scale 
on y-axis.  
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Figure 4.5 Experiment 2: Effect of SFN and TSA on CYP27B1 mRNA 
Mean ± SEM fold change of CYP27B1 mRNA in comparison to a control, at the value 
of 1.  Statistical significance notation: a= p<0.05 vs. control, b=p<0.05 vs. vitamin D 
alone vs. vitamin D and HDACI.  
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CHAPTER 5 
DISCUSSION 
The main objective of this study was to determine the effects of histone 
deacetylase inhibitors (HDACI), trichostatin A (TSA) and sulforaphane (SFN) on the 
expression of certain genes involved in vitamin D action in MCF-7 human breast 
cancer cells, and to what extent co-treatment of HDACI with the active vitamin D 
hormone, 1,25(OH)2D3  affected vitamin D-dependent gene expression. Our central 
hypothesis was that co-treatment with 1,25(OH)2D3 and either TSA or SFN would 
increase gene expression of VDR, CYP24A1, CYP27B1 and TRPV6 in MCF-7 cells.   
Histone acetylation and deacetylation are dynamic epigenetic processes due 
to the counteracting effects of nuclear histone acetylase and histone deacetylase 
enzymes, which can influence gene expression by changing the local binding of DNA 
to histone proteins in the nucleosome. Acetylation of histone proteins results in a 
less condensed chromatin structure, which can alter the interaction of DNA with 
proteins in the transcriptional machinery in the cell nucleus leading to an increase 
in gene expression. An increase in understanding about the importance of 
epigenetic changes in gene expression has led to increased clinical interest in 
evaluating compounds that can affect histone status as potential chemo-preventive 
or chemotherapeutic agents in cancer. Preclinical studies with HDACI in various 
cancer cell and animal models have been encouraging because they indicate that 
HDACI may have a preferential effect on cancerous versus normal cells (Dashwood 
& Ho, 2007) and may slow cancer cell replication. (Davis & Ross, 2007) The 
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mechanism underlying the effects of HDACI on the growth of cancer cells is not 
completely understood. Interestingly, however, studies of HDACI have found that 
they affect the expression of only a relatively small subset of genes.  (Johnson, 
Chung, & Trump, 2010) Although the control of cell growth in cancer is complex, one 
important factor appears to be the reduced expression of “tumor suppressor” genes. 
(Lopes et al., 2010) Restoration of the expression of these tumor suppressor genes 
in cancer cells may be an important avenue in the future for cancer prevention and 
treatment and has spurred on clinical trials of the relative effectiveness of these 
potentially therapeutic compounds in various types of cancers. (Marks & Breslow, 
2007) The active hormone metabolite of vitamin D is well known to have pleiotropic 
effects on cells, including being anti-proliferative (C. M. Banwell, Singh, Stewart, 
Uskokovic, & Campbell, 2003; Deeb, Trump, & Johnson, 2007) and pro-apoptotic 
(Swami et al., 2012) , and is currently being investigated in ongoing clinical trials in 
certain cancer types. The action of 1,25(OH)2D3 on cells is mediated by the vitamin D 
receptor (VDR), which is a steroid hormone intracellular transcription factor. 
Alteration in cellular VDR content has been shown to influence cellular 1,25(OH)2D3 
responsiveness. (Essa et al., 2012; Matilainen, Malinen, Turunen, Carlberg, & 
Vaisanen, 2010) Thus, lower expression of VDR would be expected to affect vitamin 
D responsiveness in both normal and cancer cells. Compared to normal cells, 
reduced VDR expression has been found in many tumor cells and has been 
suspected as a possible modulator of tumor growth. (Lopes, Paredes, Costa, Ylstra, & 
Schmitt, 2012) For example, studies have reported a moderate down-regulation of 
VDR expression in breast tissue carcinomas. (M. G. Anderson, Nakane, Ruan, 
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Kroeger, & Wu-Wong, 2006; Lopes et al., 2010)  Moreover, supportive in vivo 
evidence for a role of the VDR in cancer prevention is the observation that the 
induction of tumors in VDR knockout mice is greater than in control mice 
(Dashwood & Ho, 2007) , supporting a role for the VDR as a possible tumor 
suppressor gene.  The normal action of the VDR in the nucleus requires the action of 
a nuclear histone acetylase to bring about gene transcription. (P. H. Anderson, May, 
& Morris, 2003) Given the above information, we hypothesized that HDACI 
treatment would increase vitamin D-induced gene expression in MCF-7 human 
breast cancer cells. 
5.1 Treatment Effects on VDR Gene Expression 
In both Experiment 1 and Experiment 2 we investigated the effects of TSA 
alone and in combination with 1,25(OH)2D3 on VDR mRNA. We found that TSA 
treatment significantly increased VDR mRNA in each of these experiments by 11- 
and 12.6-fold, respectively.  This observation would suggest that 1,25(OH)2D3 – 
induced cell signaling should be increased in TSA-treated cells. This notion is 
consistent with our observations in Experiment 1 where there was a ~2-fold higher 
VDR mRNA expression in MCF-7 cells treated with both TSA and 1,25(OH)2D3 
compared to 1,25(OH)2D3 alone.  Although not statistically significant, we observed 
a similar trend in Experiment 2 where there was a ~3-fold higher VDR mRNA 
expression in cells treated with both TSA and 1,25(OH)2D3 compared to 
1,25(OH)2D3 alone.  Banwell and colleagues (C. Banwell, O'Neill, Uskokovic, & 
Campbell, 2004) had previously reported that a combination treatment of 1nmol/L 
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1,25(OH)2D3 plus 15nmol/L TSA administered for 36 hours to the relatively vitamin 
D-resistant breast cancer cell line MBD-MB-231 yielded only a 0.1 fold increase of 
VDR gene expression. (C. Banwell, O'Neill, Uskokovic, & Campbell, 2004) A study in 
malignant melanoma cells found that a co-treatment of 1,25(OH)2D3 and TSA 
modulated VDR mRNA expression in both 1,25(OH)2D3 receptive and resistant cell 
lines. (Essa et al., 2012) Overall, our findings and those of others suggest that the 
biologic actions of 1,25(OH)2D3 in some cancer cells may be enhanced by co-
treatment with TSA or other HDACIs.  This observation also suggests that epigenetic 
mechanisms may be at play under basal conditions to limit the expression of VDR 
and that TSA may be useful in other contexts where there is a need to increase VDR 
expression, such as in the elderly who may have lower intestinal expression of VDR 
that could limit cellular response to 1,25(OH)2D3. Rashid and coworker (Rashid et 
al., 2001) reported that low dose treatment with HDACIs (sodium butyrate or TSA) 
in combination with 1,25(OH)2D3 synergized to inhibit the growth of LNCaP, PC-3 
and DU-145 prostate cancer cells. There has also been evidence that TSA alone 
exhibits anti-proliferative properties in breast cancer cells. (Drzewiecka & 
Jagodzinski, 2012; Tavakoli-Yaraki, Karami-Tehrani, Salimi, & Sirati-Sabet, 2013)  
Since our research shows a significant increase in VDR mRNA in MCF-7 cells in 
response to TSA, this may, at least in part, be a reason behind TSA’s growth 
inhibitory effects. Further research with different breast cancer cells lines are 
needed to confirm these findings across different cancer cell types, as well as to 
investigate the possible benefits of combined treatment in various animal cancer 
models.  In the context of breast cancer, it should also be noted that the expression 
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of estrogen receptor-β is often epigenetically silenced and leads to tamoxifen 
resistance. TSA treatment can increase the expression of estrogen receptor-β and 
restore responsiveness to tamoxifen and other anti-estrogen agents. (Pitta, 
Papageorgis, Charalambous, & Constantinou, 2013; Tu et al., 2012) A similar 
scenario in breast cancer cells with reduced VDR expression should be investigated.  
Based on the demonstration that SFN has histone deacetylase inhibitor 
activity (Li et al., 2010b; M. Myzak, Karplus, Chung, & Dashwood, 2004; Pledgie-
Tracy, Sobolewski, & Davidson, 2007) , we expected that SFN would have similar 
effects to TSA in MCF-7 cells. However, we found that SFN treatment alone had no 
effect on VDR mRNA. In addition, co-treatment of SFN and 1,25(OH)2D3 led to 
significantly lower VDR mRNA levels than with 1,25(OH)2D3  alone. The reason for 
the discrepancy in the response of VDR gene expression to these two HDACI in MCF-
7 cells is unknown. The effects of SFN on vitamin D-induced gene expression have 
not been previously addressed in this human breast cancer cell line. In vitro, SFN has 
apoptotic properties similar to TSA (Meeran, Patel, & Tollefsbol, 2010; Pledgie-
Tracy, Sobolewski, & Davidson, 2007) ; so our conflicting results suggest that SFN 
may not have a strong enough HDACI effect on MCF-7 cells, or perhaps our dosage 
and treatment time needs to be increased. Additional studies will be needed to 
directly assess HDACI activity of SFN compared to TSA in MCF-7 cells. Differences in 
bioavailability of SFN in MCF-7 cells may exist due to differences in membrane 
transport or metabolism of these two compounds.   
Discordant findings between Experiment 1 and Experiment 2 were observed 
when cells were treated with 1,25(OH)2D3 alone. In Experiment 1, 1,25(OH)2D3 
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treatment had no effect. In contrast, in Experiment 2, 1,25(OH)2D3 treatment led to a 
significant  6-fold increase in VDR mRNA. The reason for the more robust response 
to 1,25(OH)2D3 in the second experiment is unknown. Clearly, 1,25(OH)2D3 was able 
to affect gene expression in Experiment 1 because the expression of CYP24A1, a 
highly vitamin D-responsive gene, was markedly increased, ruling out inactivity of 
the hormone.  
5.2 Treatment Effects on CYP24A1 Gene Expression 
Treatment with either HDACI alone caused a significant induction of 
CYP24A1 expression.  The physiologic effect of increased CYP24A1 expression is to 
dampen the vitamin D signal in cells by initiating catabolism of the active hormone.  
Thus, the end result of HDACI treatment on vitamin D-mediated cell function needs 
further detailed study.  Treatment of MCF-7 breast cancer cells with TSA alone on 
CYP24A1 expression has not been previously examined, but Luo and colleagues 
(Luo et al., 2010) found similar results in prostate cancer cells, where doses of TSA 
half as much as were used in these experiments were capable of inducing CYP24A1 
gene expression.  In Experiment 2, we found that SFN treatment increased CYP24A1 
expression to a similar extent as TSA.  These observations demonstrating a 
consistent effect of HDACI on CYP24A1 expression in MCF-7 cells suggest that 
epigenetic mechanisms affecting histone acetylation status may be causing CYP24A1 
expression to be silenced in the basal state. However, we found no evidence of a 
significant increase in CYP24A1 expression with co-treatment of 1,25(OH)2D3 and 
HDACI.  
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The CYP24A1 gene is known as the strongest 1,25(OH)2D3 responsive gene, 
and is commonly used to assess changes in cellular vitamin D signaling. The ability 
of 1,25(OH)2D3 treatment to induce CYP24A1 mRNA in MCF-7 cells was consistent in 
both experiments, although relative vitamin D-induced CYP24A1 expression was 
much greater in Experiment 2.  Induction of CYP24A1 by 1,25(OH)2D3 was expected 
and is in agreement with a recent study in MCF-7 cells. (Matilainen, Malinen, 
Turunen, Carlberg, & Vaisanen, 2010)  Some researchers have found that expression 
of CYP24A1 in breast carcinoma cells is down regulated,  (M. G. Anderson, Nakane, 
Ruan, Kroeger, & Wu-Wong, 2006) , but other studies conclude that expression of 
this gene is up regulated in cancer cells (Lopes et al., 2010). The reason for these 
apparent differences is not evident, but could be differences in estrogen receptor 
status in different breast cancer cell lines. Overall, the lack of an increase in vitamin 
D-induced CYP24A1 mRNA following co-treatment with 1,25(OH)2D3 and HDACI is 
contrary to our working hypothesis that HDACI would increase vitamin D-induced 
gene expression.  
5.3 Treatment Effects on CYP27B1 Gene Expression 
In Experiment 2, we investigated the effects of 1,25(OH)2D3 and HDACI on 
CYP27B1 expression. The CYP27B1 gene codes for the 1-α hydroxylase enzyme that 
activates the 25(OH)D prohormone to the active hormone 1,25(OH)2D3. An increase 
in cellular CYP27B1 expression could lead to an increase in cellular 1,25(OH)2D3 due 
to increased cellular conversion of 25(OH)D to the active hormone. This particular 
possibility was not investigated in the current experiments. We found that neither 
  46
HDACI affected CYP27B1 expression in MCF-7 cells. However, 1,25(OH)2D3 
treatment caused a significant ~7-fold increase in expression.  
A previous study done with MCF-7 cell tumors in rats with exposure to 
25(OH)D, found that after feeding a 5000 IU/kg high vitamin D3 supplemented diet, 
the tumor cells had an increased expression of CYP27B1 mRNA, indicating that a 
xenograph of MCF-7 cells could still actively potentially synthesize 1,25(OH)2D3 in 
the presence of 25(OH)D. (Swami et al., 2012) This observation is important 
because it suggests that treatment with a non-toxic dose of vitamin D could be 
useful therapeutically. Research also shows that carcinoma cells will often show 
down-regulated expression of CYP27B1. (Lopes et al., 2010) Our results suggest that 
short-term 1,25(OH)2D3 or a vitamin D analog drug treatment could be useful to 
raise CYP27B1 expression to enhance the anti-cancer effects of endogenous vitamin 
D or vitamin D supplementation.  
We found that combination treatment of TSA with 1,25(OH)2D3 did not 
further increase vitamin D-induced CYP27B1 expression. In contrast, co-treatment 
with both SFN and 1,25(OH)2D3  inhibited vitamin D-induced CYP27B1 expression. 
The reason for this discrepancy in the action of TSA and SFN on vitamin D-induced 
CYP27B1 expression is unknown. To our knowledge, the effects of HDACIs on 
CYP27B1 gene expression have not been previously examined. Since a reduction in 
CYP27B1 by SFN under in vivo conditions could have detrimental effects on vitamin 
D action, further study of this relationship is warranted. This is particularly true in 
light of the fact that SFN is a bioactive food component found in cruciferous 
vegetables, such as broccoli, cabbage, etc.  
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5.4 Treatment Effects on TRPV6 Gene Expression 
In both experiments, the expression of TRPV6 mRNA was apparently absent 
in most samples. Recent research has concluded, however, that elevated TRPV6 
expression is common in estrogen receptor negative breast cancer cells lines 
(Ouadid-Ahidouch, Dhennin-Duthille, Gautier, Sevestre, & Ahidouch, 2012; Peters et 
al., 2012) ; so one explanation for our null finding in MCF-7 cells is that they are 
estrogen receptor positive, and would not necessarily share similar TRPV6 gene 
expression characteristics with estrogen receptor negative breast cancer cells.  
Additional investigation of this notion is needed.  
5.5 Limitations 
There are a few limitations with the work presented that are important to 
discuss. Due to constraints with time and resources, we were only able to complete 
two experiments with a relatively small sample size for each. Seeing conflicting 
results between Experiment 1 and 2 in regards to VDR gene expression with the 
1,25(OH)2D3 treatment, leads us to believe that additional study is needed to have a 
more solid understanding of HDACI effects on VDR mRNA in MCF-7 cells. 
Another possible limitation in our research was our treatment dosages and 
how they relate to biological serum levels. Our treatment dosage of 1,25(OH)2D3 
was 10 nmol/L, which is ~1000 times higher than the typical circulating 
1,25(OH)2D3 concentration. However, this dose of 1,25(OH)2D3 is commonly used in 
cell culture experiments and does not represent the top of the dose-response curve 
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for many vitamin D-induced actions in cultured cells. The TSA dose was 1 µmol/L, 
which is a relatively high dose, and many cellular effects of TSA can be seen at lower 
doses. The SFN dose was 20 µmol/L and is in the range used in many other cell 
culture studies. However, serum SFN concentration after a meal of cruciferous 
vegetables may be much lower.   
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CHAPTER 6 
SUMMARY AND CONCLUSIONS 
At the conclusion of our study, we have gained insight into the, as of yet, 
undefined effects that the histone deacetylase inhibitors TSA and SFN have on 
vitamin D-modulated gene expression, and their ability to work with 1,25(OH)2D3 to 
alter overall gene expression of CYP24A1, CYP27B1, and VDR in MCF-7 breast 
cancer cells. Since an overall trend of down-regulation in vitamin D modulated gene 
expression is often seen in breast cancer cells (Lopes et al., 2010), the ability of 
HDACI to effect epigenetic changes in cells may be important to optimize vitamin D’s 
anti-proliferative effects in cancer cells. TSA is already being used as a co-treatment 
in cancer therapy. Vorinostat, which is a laboratory developed compound with the 
same chemical structure to TSA, is being studied in hundreds of clinical trials. 
(Marks & Breslow, 2007) The findings from these clinical studies are showing that 
TSA has HDACI effects and is capable of increasing the therapeutic effects of 
different anti-cancer hormone therapies. Although much more work is needed, our 
preliminary study of TSA in MCF-7 cells suggests that TSA may have useful 
properties to modulate therapeutic responses to vitamin D-based breast cancer 
therapies by increasing VDR gene expression. An important next step in our 
research would be to show that TSA increases VDR protein in MCF-7 cells and 
potentiates the anti-cancer effects of vitamin D hormone or vitamin D analogs.  
This is one of the first studies to look at SFN as a HDACI in co-treatment with 
1,25(OH)2D3. Our working hypothesis was based upon the findings from previous 
research that SFN has HDACI activity. (M. C. Myzak, Tong, Dashwood, Dashwood, & 
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Ho, 2007) We expected that SFN and TSA would act through a similar epigenetic 
mechanism and would have similar effects in MCF-7 cells. However, the apparent 
inhibition by SFN of vitamin D-induced VDR and CYP27B1 expression was totally 
unexpected. Additional study will be needed to understand why TSA and SFN had 
different effects on vitamin D-induced VDR and CYP27B1 expression.  Despite this, 
cancer prevention research with SFN has been producing positive results; SFN has 
been seen to inhibit HDAC activity in human colon, prostate and breast cancer cells 
lines, as well as induce histone hyperacetylation; both of which are linked to 
regulate proliferation, differentiation and apoptosis in cancer cells lines. (Anwar-
Mohamed & El-Kadi, 2009; Kim & Singh, 2009; Meeran, Patel, & Tollefsbol, 2010; M. 
C. Myzak, Tong, Dashwood, Dashwood, & Ho, 2007; Pledgie-Tracy, Sobolewski, & 
Davidson, 2007) But our conclusions force us to examine the role that HDACI plays 
on cellular vitamin D metabolism in a different way. Working at a cellular level may 
not be the best platform for this research, examining the relationship in vivo may 
yield some new evidence.  
6.1 Further Research  
The results from this research have allowed us to gain additional knowledge 
about the interactions between 1,25(OH)2D3 and two HDACI, TSA and SFN in vitro; 
but there are many more interactions that should be explored to fully understand 
these mechanisms. It would be important to investigate the effects of circulating 
vitamin D, 25-hydroxyvitamin D, especially in a co-treatment with TSA and SFN in 
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regards to CYP27B1 gene expression to see if the inactive form of vitamin D and a 
HDACI can raise expression higher than we saw with the 1,25(OH)2D3 treatment. 
It would also be important to look at the dose dependent reactions of these 
treatments; there is limited understanding gained from only one treatment dose. 
Since our SFN treatment yielded only slight changes, it would be important to raise 
that dose as well to identify maximum responses. However, the issue of cellular 
toxicity may limit raising the HDACI dose.  
Continued research will increase our understanding of the interaction taking 
place between 1,25(OH)2D3, TSA and SFN; and their impact on vitamin D mediated 
gene expression, as well as cancer cell proliferation, differentiation and apoptosis. 
This knowledge could eventually aid us in the formation of new treatments and 
prevention strategies against the deadly disease, cancer. 
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APPENDIX A 
TREATMENT CALCULATIONS  
Vitamin D (Enzo: BML-DM200-0050) 
Stock Solution  50μg in 50μL EtOH 
=2.4mM (2.4x10-3) 
Working Solution  Dilute to 1:1,000  
2μL stock solution in 2,000μL (2mL) EtOH 
=2.4μM (2.4x10-6 M) 
Treatment Solution  Dilute 4.2μL working solution in 1mL Media 
 
Trichostatin A (TSA) Sigma T8552-1MG (10mM in 330μM in EtOH) 
Stock Solution  10mM concentration  
Working Solution  5μL stock solution in 500 μL EtOH = 100μM 
concentration 
Treatment Solution  10μL working solution in 1mL media 
  
L-Sulforaphane (SFN) (Sigma: S6317) 
Stock Solution  20mM in DMSO 
Treatment Solution 20μmol/L = 1μL working solution in 1mL media 
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APPENDIX B 
LABORATORY PROTOCOLS 
RNA Isolation (Make sure to use all autoclaved supplies) 
1. Cell Harvest 
a. Remove the media 
b. Use 1mL Tri-Reagent (Trizol) per well (in 6-well plate) 
c. Scratch the cells from the well with a cell scraper 
d. Pipet suspension till thick and stringy, transfer to eppendorf tubes 
e. Can then be frozen at -80°C 
f. Keep 5 minutes at room temp or warm water bath to thaw when 
ready to complete separation phase 
2. Phase Separation (Keep on ice between steps) 
a. Add 150μL chloroform reagent to the homogenate  
b. Invert vigorously for 15 seconds 
c. Allow the mixture to sit at room temperature for 5 minutes 
d. Centrifuge at 12,000g for 15 minutes at 4°C 
3. RNA Precipitation  
a. Transfer the aqueous phase to a fresh 1.5mL eppendorf tube 
i. RNA is the top clear aqueous layer, white strip is DNA in the 
interphase and bottom pink is protein in the organic phase 
b. Add 0.5mL of 100% isopropanol and mix gently by inversion 
c. Keep on ice for 15 minutes 
d. Centrifuge at 12,000 g for 20 min at 4°C 
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4. RNA Washing and Solubilization  
a. Remove the supernatant (all liquid above small pellet on bottom, be 
careful not to disturb the pellet, may appear white or as a clear gel) 
b. Add 1mL of 75% Ethanol (EtOH) (made with Milli-Q water) 
c. Kick samples at the bottom to dislodge the pellet 
d. Centrifuge at 7,500 g for 5 minutes at 4°C 
e. Remove EtOH: pipette the solution out but be careful not to lose the 
pellet at the bottom, and pipette the rest out with a 200μL pipette 
f. Briefly spin samples down, remove the remaining liquid with a 10μL 
pipette  
g. Air dry: keep samples open for several minutes, don’t dry completely  
h. Add 40μL of Milli-Q water (or DEPC treated water), invert and spin 
down 
i. Incubate 10 minutes at 56°C to make RNA molecule spread evenly and 
then keep on ice for several minutes 
RNA Quantification 
1. Combine 498μL Milli-Q water and 2μL of RNA sample together in eppendorf 
tubes 
2. On spectrophotometer 
a. Turn on the machine (Allow about 10 minutes to boot up) 
b. Press 7 = BioMethods 
c. Press 1 = DNA Quantification 
d. Rinse cuvette very well to remove ethanol and dry with Kim wipes 
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e. Blank the spectrometer with 500μL Milli-Q water 
f. Press start to test blank is at 0.000 
g. Run samples and record A260, A280 (A320 can identify 
contamination) and the ratio. The A260/A280 ratio should be 
between 1.5-1.8 
3. Enter A260 and A 280 readings into “RNA Concentration” excel spreadsheet 
4. The concentration of RNA is A260 of 10 x μg/μL because the A260 of 40 μg/mL 
RNA samples equals to 1 
5. Dilute RNA samples to 1μg RNA/4.75μL we need at least 2μg RNA for PCR 
First Strand cDNA Synthesis 
1. The following procedure is designed to convert 5μg of total RNA into first-
strand cDNA 
2. Mix and briefly centrifuge each component before each use 
3. Combine the following in 0.2 or 0.5mL RNAased tube (will add up to 10μL) 
a. 1μL Primer: 50μM oligo(dT)  
b. 1μL 10mM dNTP mix 
c. 8μL 5μg RNA and DEPC water (information found in Excel 
Spreadsheet) 
d. Incubate at 65°C for 5 minutes, then place on ice for at least 1 minute. 
(Protocol Library: Kim pre-cDNA) 
4. Prepare the following cDNA Synthesis Mix, adding each component in the 
indicated order (listed are amounts for 1 reaction) 
a. 2μL 10X RT buffer 
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b. 4μL 25mM MgCl2 
c. 2μL 0.1 M DTT 
d. 1μL RNaseOUT (40 U/μL) 
e. 1μL SuperScript III-RT (200 U/μL) 
5. Add 10μL of cDNA Synthesis Mix to each RNA/ primer mixture; mix gently 
and collect by brief centrifuge.  
6. Incubate as follows: (Protocol Library: Kim cDNA) 
a. 10 minute at 25°C followed by 
b. 50 minutes at 50°C 
c. Terminate the reaction at 85°C for 5 minutes, then chill on ice 
7. Collect the reactions by brief centrifuge. Add 1μL of RNase H to each tube and 
incubate for 20 minutes at 37°C (Protocol Library: RNaseH) 
8. cDNA synthesis reactions can be stored at -30°C to -10°C or used for PCR 
immediately 
Real Time qPCR 
1. cDNA quantification 
a.  Add 1μL of each cDNA sample to 499μL Milli-Q Water in eppendorf 
tubes 
b. Use spectrophotometer to obtain A=260 and A=280 
c. Use “DNA Quantification” excel spreadsheet 
i. (A280/.027) x 500 = cDNA concentration 
ii. cDNA concentration/50 = Total volume of sample containing 
50μg/mL cDNA 
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iii. Total Volume - 1μL cDNA = Volume of Milli-Q Water to add to 
1μL cDNA to have each sample have 50μg/mL cDNA 
2.  Correcting cDNA concentration 
a. Add 1μL of each cDNA sample to new PCR tube 
b. Add the amount of Milli-Q water specified in “DNA Quantification” 
excel spreadsheet to bring samples to the same concentration 
(50μg/mL cDNA) 
3. Preparation of Master Mix (in eppendorf tube): each qPCR reaction will have 
20μL total 
a. 10μL TaqMan Gene Expression Master Mix 
i. Applied Biosystems #4369016 
b.  1μL TaqMan Gene Expression Assay: Housekeeping-GAPDH (VIC dye) 
i. Applied Biosystems Hs99999905_m1 
c. 1μL TaqMan Gene Expression Assay 
i. Target-CYP24A1 with FAM dye 
1. Applied Biosystems Hs00167999_m1 
ii. Target-CYP27B1 with FAM dye 
1. Applied Biosystems Hs00168017_m1 
iii. Target- TRPV6 with FAM dye 
1. Applied Biosystems Hs01114089_g1 
iv. Target-VDR with FAM dye 
1. Applied Biosystems Hs00172113_m1 
d. 4μL Milli-Q Water 
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e. Added later to reaction plate: 4μL cDNA (200ng/mL total cDNA) 
4. Preparation of qPCR plate 
a.  Pipette 16μL of prepared master mix (from eppendorf tube) into each 
reaction well in 96 well plate 
i. Applied Biosystems #4346906 
b. Pipette 4μL of cDNA sample into each reaction well (run in triplicate) 
c. Cover plate with 96 well plate cover 
i. Applied Biosystems #4360954 
d. Tear off white ends of plate cover and smooth out plate cover with a 
“plate cover smoother” so that it adheres to the plate 
e. Centrifuge plate in plate spinner (make sure it’s balanced) for 30 
seconds 
5.  StepOnePlus Real-Time PCR System 
a. Turn on machine 
b. Place plate into machine making sure the numbers and letters are 
lined up 
c. Make sure machine has fully turned on (takes 15 minutes) 
d. Click on StepOne Software v2.0 on desktop 
e. Click advanced step up 
f. For tab “Experiment Properties” 
i. Create name for experiment (experiment # and target gene) 
ii. Make sure the following settings are clicked: 
1. StepOnePlus (96 wells) 
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2. Quantitation-comparative Ct (ΔΔCt) 
3. TaqMan Reagents 
4. Standard (~2 hours) 
g. For tab “PLATE-SET UP” 
i. Make two targets: One is the housekeeping gene (GAPDH), 
with VIC dye selected, target gene should have FAM dye 
selected 
ii. Add the number of samples wells you have 
iii. Click “Assign Targets and Samples” 
1. Assign samples to the wells that they are in, assign each 
triplicate as one sample, and all control wells as one 
sample; double check these 
2. Assign both GAPDH and target to all sample wells 
3. Select ROX dye for passive reference 
h.  Click “Start Run”  
i. Make sure the machine actually starts the reaction 
i.  Come back in two hours to check status of reaction, discard plate and 
export data to the desired place 
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